References
- Lipton RB , BuseDC , SerranoD , HollandS , ReedML . Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study . Headache53 ( 8 ), 1300 – 1311 ( 2013 ).
- Gilmore B , MichaelM . Treatment of acute migraine headache . Am. Fam. Phys.83 ( 3 ), 271 – 280 ( 2011 ).
- Marmura MJ , SilbersteinSD , SchwedtTJ . The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies . Headache55 ( 1 ), 3 – 20 ( 2015 ).
- Evers S , AfraJ , FreseAet al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force . Eur. J. Neurol.16 ( 9 ), 968 – 981 ( 2009 ).
- Dahlof CG . Non-oral formulations of triptans and their use in acute migraine . Curr. Pain Headache Rep.9 ( 3 ), 206 – 212 ( 2005 ).
- Houghton LA , FowlerP , KeeneON , ReadNW . Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man . Aliment. Pharmacol. Ther.6 ( 6 ), 685 – 691 ( 1992 ).
- Cipolla G , SaccoS , CremaF , MoroE , De PontiF , FrigoG . Gastric motor effects of triptans: open questions and future perspectives . Pharmacol. Res.43 ( 3 ), 205 – 210 ( 2001 ).
- Tack J . The physiology and the pathophysiology of the gastric accommodation reflex in man . Verhandelingen62 ( 3 ), 183 – 207 ; discussion 207–110 ( 2000 ).
- Scott AK . Sumatriptan clinical pharmacokinetics . Clin. Pharmacokinet.27 ( 5 ), 337 – 344 ( 1994 ).
- ONZETRA Xsail, package Insert . Avanir Pharmaceuticals, Inc. , CA, USA ( 2016 ).
- Munjal S , GautamA , OffmanE , Brand-SchieberE , AllenbyK , FisherDM . A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults . Headache56 ( 9 ), 1455 – 1465 ( 2016 ).
- Yates R , NairnK , DixonR , KempJV , DaneAL . Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers . J. Clin. Pharmacol.42 ( 11 ), 1244 – 1250 ( 2002 ).
- Zomig, package insert . Impax Pharmaceuticals , CA, USA ( 2012 ).
- Lionetto L , CasollaB , MastropietriFet al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines . Expert Opin. Drug Metab. Toxicol.8 ( 8 ), 1043 – 1050 ( 2012 ).
- Lionetto L , NegroA , CasollaB , SimmacoM , MartellettiP . Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice . Expert Opin. Pharmacother.13 ( 16 ), 2369 – 2380 ( 2012 ).
- Ferrari MD , GoadsbyPJ , RoonKI , LiptonRB . Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials . Cephalalgia22 ( 8 ), 633 – 658 ( 2002 ).
- Rosenzweig P , BrohierS , ZipfelA . The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies . Clin. Pharmacol. Ther.54 ( 5 ), 578 – 583 ( 1993 ).
- Lutfullin A , KuhlmannJ , WensingG . Adverse events in volunteers participating in Phase I clinical trials: a single-center five-year survey in 1,559 subjects . Int. J. Clin. Pharmacol. Ther.43 ( 5 ), 217 – 226 ( 2005 ).
- Sibille M , DeigatN , JaninA , KirkesseliS , DurandDV . Adverse events in phase-I studies: a report in 1015 healthy volunteers . Eur. J. Clin. Pharmacol.54 ( 1 ), 13 – 20 ( 1998 ).